Management of primary mycotic aneurysms and prosthetic graft infections: an 8-year experience with in-situ cryopreserved allograft reconstruction.


Journal

ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634

Informations de publication

Date de publication:
09 2020
Historique:
received: 03 09 2019
revised: 16 07 2020
accepted: 19 07 2020
pubmed: 13 8 2020
medline: 15 5 2021
entrez: 13 8 2020
Statut: ppublish

Résumé

Primary mycotic aneurysms and prosthetic graft infections are traditionally managed by resection of infected vascular tissue and revascularisation with an extra-anatomical bypass. Long-term patency for this method has been reported to be poor with associated high reinfection and limb amputation rates. The aim of this study was to analyse the outcomes of those patients in our department between 2010 and 2018 whom had revascularisation with in-situ arterial reconstruction using cryopreserved allograft as a conduit. The data were retrospectively reviewed and 13 patients were identified. There were five patients with primary mycotic aneurysms and eight patients with prosthetic graft infections, three of which were complicated by aortoenteric fistulae (AEF). There were three peri-operative mortalities (23%) with all three mortalities related to graft re-infection and post-implantation haemorrhage; two of these from uncontrolled bile leaks related to the original AEF with persistent graft contamination. The 10 surviving patients were followed up for a mean duration of 15.8 months with an overall primary graft patency of 89% and no incidence of graft re-infection or aneurysmal degeneration. Patients that survived the peri-operative period demonstrated acceptable medium-term allograft durability, with the most favourable outcomes observed in those patients who had arterial infections uncomplicated by AEF. The main barrier to more wide-spread use in our state remains inadequate supply of banked cryopreserved tissue.

Sections du résumé

BACKGROUND
Primary mycotic aneurysms and prosthetic graft infections are traditionally managed by resection of infected vascular tissue and revascularisation with an extra-anatomical bypass. Long-term patency for this method has been reported to be poor with associated high reinfection and limb amputation rates. The aim of this study was to analyse the outcomes of those patients in our department between 2010 and 2018 whom had revascularisation with in-situ arterial reconstruction using cryopreserved allograft as a conduit.
METHODS
The data were retrospectively reviewed and 13 patients were identified. There were five patients with primary mycotic aneurysms and eight patients with prosthetic graft infections, three of which were complicated by aortoenteric fistulae (AEF).
RESULTS
There were three peri-operative mortalities (23%) with all three mortalities related to graft re-infection and post-implantation haemorrhage; two of these from uncontrolled bile leaks related to the original AEF with persistent graft contamination. The 10 surviving patients were followed up for a mean duration of 15.8 months with an overall primary graft patency of 89% and no incidence of graft re-infection or aneurysmal degeneration.
CONCLUSION
Patients that survived the peri-operative period demonstrated acceptable medium-term allograft durability, with the most favourable outcomes observed in those patients who had arterial infections uncomplicated by AEF. The main barrier to more wide-spread use in our state remains inadequate supply of banked cryopreserved tissue.

Identifiants

pubmed: 32783268
doi: 10.1111/ans.16218
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1716-1720

Informations de copyright

© 2020 Royal Australasian College of Surgeons.

Références

Marston W, Risley G, Criado E, Burnham S, Keagy B. Management of failed and infected axillofemoral grafts. J. Vasc. Surg. 1994; 20: 357-65.
Brown K, Heyer K, Rodriguez H, Eskandari M, Pearce W, Morasch M. Arterial reconstruction with cryopreserved human allografts in the setting of infection: a single centre experience with midterm follow up. J. Vasc. Surg. 2009; 49: 660-6.
Vogt P, Brunner-La Rocca H, Carrel T et al. Cryopreserved arterial allografts in the treatment of major vascular infection: a comparison with conventional surgical techniques. J. Thorac. Cardiovasc. Surg. 1998; 116: 965-72.
Bisdas T, Bredt M, Pichlmaier M et al. Eight-year experience with cryopreserved arterial homografts for the in-situ reconstruction of abdominal aortic infections. J. Vasc. Surg. 2010; 52: 323-30.
Leseche G, Castier Y, Petit M et al. Long-term results of cryopreserved arterial allograft reconstruction in infected prosthetic grafts and mycotic aneurysms of the abdominal aorta. J. Vasc. Surg. 2001; 34: 616-22.
Lavigne J, Postal A, Kohl P, Limet R. Prosthetic vascular infection complicated or not by aortoenteric fistula: comparison of treatment with and without cryopreserved allograft (homograft). Eur. J. Vasc. Endovasc. Surg. 2003; 25: 416-23.
Noel A, Gloviczki P, Cherry K et al. Abdominal aortic reconstruction in infected fields: early results of the United States cryopreserved aortic allograft registry. J. Vasc. Surg. 2002; 34: 419-20.
Ali A, Modrall G, Hocking J et al. Long-term results of the treatment of aortic graft infection by in situ replacement with femoral popliteal vein grafts. J. Vasc. Surg. 2008; 50: 30-9.
Cascio A, De Caridi G, Lentini S et al. Involvement of the aorta in brucellosis: the forgetten, life threatening complication. A systematic review. Vector Borne Zoonotic Dis. 2012; 12: 827-40.
Kan C, Lee H, Yang Y. Outcome after endovascular stent graft treatment for mycotic aortic aneurysm: a systemic review. J. Vasc. Surg. 2007; 46: 906-12.
Sorellus K, Mani K, Björck M et al. Endovascular treatment of mycotic aortic aneurysms: a European multicenter study. Circulation 2014; 130: 2136-42.
Vogt P, Brunner-La-Rocca H, Lachat M, Ruef C, Turina M. Technical details with the use of cryopreserved arterial allografts for aortic infection: influence on early and midterm mortality. J. Vasc. Surg. 2002; 35: 80-6.
Veal A, Oshin O, Schober M, Rowbern S, Torella F. Cryopreserved superficial femoral artery homografts for aortoiliac segment replacement in infection. Vascular 2013; 22: 65-7.
Abbas K, Davies J, Kabir I, Ahmad M, B M, Cavanagh S. Novel surgical reconstruction of a mycotic abdominal aortic aneurysm using cryopreserved femoral arterial allograft from the NHS tissue bank: a new resource for UK vascular surgeons. Ann. R. Coll. Surg. Engl. 2012; 94: 15-7.

Auteurs

Rohan Arasu (R)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Ian Campbell (I)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Andrew Cartmill (A)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Toby Cohen (T)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Peter Hansen (P)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Juanita Muller (J)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Richa Dave (R)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Timothy McGahan (T)

Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH